" class="no-js "lang="en-US"> Genoskin - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Genoskin | Pharmtech Focus

Genoskin

About Genoskin

Genoskin

Genoskin has developed a platform based on living human skin that enables generating human clinical data to de risk drug development. Genoskin provides researchers around the world with solutions to generate human data ahead of clinical trials.
Subcutaneous injections can even be tested on this platform to characterize the human immune response in the multiple conditions to be tested.

Our expert team follows strict regulatory guidelines to comply with all applicable regulations. All Genoskin procedures and processes are ISO9001-certified.

Related Story

News

 Genoskin Launches MANTIS

Genoskin Launches MANTIS, a Spatial Biology Imaging Platform Dedicated to Skin Immunology

December 6 2021

Genoskin, a biotechnology company that leverages live ex vivo human skin to test therapeutic and non-therapeutic products, […]

Appointments

 Genoskin Appoints Dr Nicolas Gaudenzio as Chief Scientific Officer | Pharmtech Focus

Genoskin Appoints Dr Nicolas Gaudenzio as Chief Scientific Officer

November 8 2021

Genoskin, a biotechnology company that provides transformative platforms and tools leveraging live ex vivo human skin to […]

Clinical Trials

 Genoskin Launches ISR Platform®

Genoskin Launches ISR Platform®, the First Human Skin Ex Vivo Platform to Study Injection Site Reactions (ISR)

July 7 2021

Genoskin, a biotechnology company that provides transformative platforms and tools leveraging human skin to test […]